Publications

Detailed Information

Phosphorylation of ERK1/2 and Prognosis of Clear Cell Renal Cell Carcinoma

DC Field Value Language
dc.contributor.authorLee, Hyun Ju-
dc.contributor.authorKim, Dong-Il-
dc.contributor.authorKang, Gyeong Hoon-
dc.contributor.authorKwak, Cheol-
dc.contributor.authorMoon, Kyung Chul-
dc.contributor.authorKu, Ja Hyeon-
dc.date.accessioned2012-06-04T05:35:45Z-
dc.date.available2012-06-04T05:35:45Z-
dc.date.issued2009-02-
dc.identifier.citationUROLOGY; Vol.73 2; 394-399ko_KR
dc.identifier.issn0090-4295-
dc.identifier.urihttps://hdl.handle.net/10371/76783-
dc.description.abstractOBJECTIVES To evaluate the phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) in clear cell renal cell carcinoma (CCRCC) and to investigate its prognostic significance. ERK1/2 activation had been reported in RCC, but little is known about its prognostic significance. METHODS We immunohistochemically analyzed phosphorylated ERK1/2 (pERK) expression using tissue microarrays in 328 CCRCC specimens. The percentage of tumor cells showing positive staining was evaluated and classified into 4 categories: 0, 0%; 1+, 1%-10%; 2+, 11%-50%; and 3+, >50%. For statistical analysis, the cases were subdivided into pERK-low (0 and 1+) and pERK-high (2+ and 3+) expression. RESULTS Our study showed significantly greater expression of pERK in CCRCC than in non-neoplastic renal parenchyma. pERK-high expression was significantly associated with a low pT category (P = .046). The survival analysis showed a significant association between pERK-high expression and better progression-free survival (P = .014). Furthermore, the prognostic significance of pERK expression was quite different between small CCRCC (size <= 7 cm) and large CCRCC (size >7 cm) lesions. In small CCRCC, pERK-high expression correlated significantly with better cancer-specific survival (P = .018) and better progression-free survival (P < .001). However, no correlation was found between pERK expression and survival in large CCRCC. CONCLUSIONS High expression of pERK in CCRCC was associated with a low pT category and showed a longer progression-free survival, especially in small CCRCC. Although the biologic mechanism of the ERK pathway in CCRCC remains unknown, the results of this study suggest that pERK expression is a positive prognosticator for survival in those with small CCRCC. UROLOGY 73: 394-399, 2009. (C) 2009 Published by Elsevier Inc.ko_KR
dc.description.sponsorshipThis work was supported by grant 03-2005-004 from the Seoul National University
Hospital Research Fund.
ko_KR
dc.language.isoenko_KR
dc.publisherELSEVIER SCIENCE INCko_KR
dc.titlePhosphorylation of ERK1/2 and Prognosis of Clear Cell Renal Cell Carcinomako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이현주-
dc.contributor.AlternativeAuthor김동일-
dc.contributor.AlternativeAuthor강경훈-
dc.contributor.AlternativeAuthor곽철-
dc.contributor.AlternativeAuthor구자현-
dc.contributor.AlternativeAuthor문경철-
dc.identifier.doi10.1016/j.urology.2008.08.472-
dc.citation.journaltitleUROLOGY-
dc.description.citedreferenceSchmitz KJ, 2007, VIRCHOWS ARCH, V450, P151, DOI 10.1007/s00428-006-0342-y-
dc.description.citedreferenceWeiss RH, 2007, J UROLOGY, V177, P63, DOI 10.1016/j.juro.2006.08.073-
dc.description.citedreferenceMurphy DA, 2006, AM J PATHOL, V169, P1875, DOI 10.2353/ajpath.2006.050711-
dc.description.citedreferenceMcLaughlin JK, 2006, SEMIN ONCOL, V33, P527, DOI 10.1053/j.seminoncol.2006.06.010-
dc.description.citedreferenceShuch BM, 2006, SEMIN ONCOL, V33, P563, DOI 10.1053/j.seminoncol.2006.06.006-
dc.description.citedreferenceTorii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x-
dc.description.citedreferenceGollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002-
dc.description.citedreferenceChadha KS, 2006, ANN SURG ONCOL, V13, P933, DOI 10.1245/ASO.2006.07.011-
dc.description.citedreferenceLopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035-
dc.description.citedreferenceMilde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655-
dc.description.citedreferenceAmato RJ, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi002-
dc.description.citedreferenceWALTER MS, 2005, CANCER, V104, P2323-
dc.description.citedreferenceVicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644-
dc.description.citedreferenceHandra-Luca A, 2003, AM J PATHOL, V163, P957-
dc.description.citedreferenceBlackhall FH, 2003, CLIN CANCER RES, V9, P2241-
dc.description.citedreferenceSOBIN LH, 2002, UICC TNM CLASSIFICAT-
dc.description.citedreferencePearson G, 2001, ENDOCR REV, V22, P153-
dc.description.citedreferenceKolch W, 2000, BIOCHEM J, V351, P289-
dc.description.citedreferenceHoshino R, 1999, ONCOGENE, V18, P813-
dc.description.citedreferenceSewing A, 1997, MOL CELL BIOL, V17, P5588-
dc.description.citedreferenceOKA H, 1995, CANCER RES, V55, P4182-
dc.description.citedreferenceFUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655-
dc.description.tc3-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share